Cogent Biosciences (Cogent Biosciences) Operating Cash Flow per Share : $-1.94 (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Cogent Biosciences Operating Cash Flow per Share?

Cogent Biosciences's operating cash flow per share for the three months ended in Dec. 2023 was $-0.51. Cogent Biosciences's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.94.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 15.80% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 22.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Cogent Biosciences's Operating Cash Flow per Share or its related term are showing as below:

COGT' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -29.3 Med: 15.8 Max: 33.8
Current: 15.8

During the past 9 years, Cogent Biosciences's highest 3-Year average Operating Cash Flow per Share Growth Rate was 33.80% per year. The lowest was -29.30% per year. And the median was 15.80% per year.

COGT's 3-Year OCF Growth Rate is ranked better than
63.06% of 1237 companies
in the Biotechnology industry
Industry Median: 3.5 vs COGT: 15.80

Cogent Biosciences Operating Cash Flow per Share Historical Data

The historical data trend for Cogent Biosciences's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cogent Biosciences Operating Cash Flow per Share Chart

Cogent Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-5.45

-3.24

-1.52

-2.02

-1.93

Cogent Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.42	-0.56	-0.43	-0.44	-0.51

Competitive Comparison of Cogent Biosciences's Operating Cash Flow per Share

For the Biotechnology subindustry, Cogent Biosciences's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cogent Biosciences's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cogent Biosciences's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Cogent Biosciences's Price-to-Operating-Cash-Flow falls into.

Cogent Biosciences Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Cogent Biosciences's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-153.624	/	79.658
	=	-1.93

Cogent Biosciences's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	-44.07	/	86.808
	=	-0.51

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.94

Cogent Biosciences Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Cogent Biosciences's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Cogent Biosciences (Cogent Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cogent Biosciences Inc (NAS:COGT) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

275 Wyman Street, 3rd Floor, Waltham, MA, USA, 02451

Website

https://www.cogentbio.com

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.

Executives

Fairmount Funds Management Llc	10 percent owner, other: See Remarks	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Evan Kearns	officer: Chief Legal Officer	AGENUS INC., 3 FORBES ROAK, LEXINGTON MA 02421
John L. Green	officer: Chief Financial Officer	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
John Edward Robinson	officer: Chief Scientific Officer	C/O COGENT BIOSCIENCES, INC., 200 CAMBRIDGE PARK DRIVE, SUITE 2500, CAMBRIDGE MA 02140
Christopher W. Cain	director	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Peter Evan Harwin	director	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Arlene Morris	director	C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Todd Shegog	director	200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Jessica Sachs	officer: Chief Medical Officer	C/O UNUM THERAPEUTICS INC., 200 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Matthew Ros	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Karen Jean Ferrante	director	150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818
Andrew R Robbins	director, officer: President and CEO	C/O 3200 WALNUT ST, BOULDER CO 80301
Venrock Healthcare Capital Partners Iii, L.p.	10 percent owner	530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Vhcp Management Iii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Management Ii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018